Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionRecommendation for adults and ...
Hosted on MSN
Sanofi stock slides on Dupixent successor AD trial
Sanofi’s stock dropped in the wake of data from its Phase III trial of atopic dermatitis (AD) candidate amlitelimab, which had been touted as a potential successor to Dupixent. While the Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback